Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine

被引:107
作者
Smith, Michael P.
Fletcher-Turner, Anita
Yurek, David M.
Cass, Wayne A.
机构
[1] Univ Kentucky, Dept Anat & Neurobiol, Chandler Med Ctr, Lexington, KY 40536 USA
[2] Univ Kentucky, Dept Surg Neurosurg, Coll Med, Lexington, KY 40536 USA
关键词
dihydroxyvitamin D-3; dopamine; GDNF; 6-hydroxydopamine; striatum; substantia nigra;
D O I
10.1007/s11064-006-9048-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Calcitriol has been implicated as an agent that has neuroprotective effects in various animal models of diseases, possibly by upregulating glial cell line-derived neurotrophic factor (GDNF). The present study examined the neuroprotective effects of calcitriol in a model of early Parkinson's disease. Rats were treated daily with calcitriol or saline for 7 days before an intraventricular injection of 6-hydroxydopamine (6-OHDA), and then for 1 day or daily for 31/2 to 4 weeks after lesioning. Evoked overflow and tissue content of dopamine (DA) were determined 31/2 to 4 weeks post lesion. The 8-day calcitriol treatment did not attenuate 6-OHDA-induced decreases in evoked overflow of DA, nor did it protect against 6-OHDA-induced reductions in tissue levels of DA in the striatum or substantia nigra. However, the long-term calcitriol treatment did significantly increase evoked overflow of DA, as well as the amount of DA in the striatum, compared to saline treated animals. GDNF was significantly increased in the substantia nigra, but not in the striatum, of non-lesioned, calcitriol treated rats. These results suggest that long-term treatment with calcitriol can provide partial protection for dopaminergic neurons against the effects of intraventricularly administered 6-OHDA.
引用
收藏
页码:533 / 539
页数:7
相关论文
共 47 条
[1]   The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages [J].
Aoi, M ;
Date, I ;
Tomita, S ;
Ohmoto, T .
NEUROSCIENCE RESEARCH, 2000, 36 (04) :319-325
[2]   Prevalence of Parkinsonian signs and associated mortality in a community population of older people [J].
Bennett, DA ;
Beckett, LA ;
Murray, AM ;
Shannon, KM ;
Goetz, CG ;
Pilgrim, DM ;
Evans, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (02) :71-76
[3]   Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease [J].
Bjorklund, A ;
Rosenblad, C ;
Winkler, C ;
Kirik, D .
NEUROBIOLOGY OF DISEASE, 1997, 4 (3-4) :186-200
[4]   DEPLETION OF BRAIN NORADRENALINE AND DOPAMINE BY 6-HYDROXYDOPAMINE [J].
BREESE, GR ;
TRAYLOR, TD .
BRITISH JOURNAL OF PHARMACOLOGY, 1971, 42 (01) :88-&
[5]  
Cass WA, 2004, EXP NEUROL, V187, P205
[6]   HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat [J].
Cass, WA ;
Harned, ME ;
Peters, LE ;
Nath, A ;
Maragos, WF .
BRAIN RESEARCH, 2003, 984 (1-2) :133-142
[7]  
Cass WA, 1999, J NEUROSCI, V19, P1416
[8]   Prospects for new restorative and neuroprotective treatments in Parkinson's disease [J].
Dunnett, SB ;
Björklund, A .
NATURE, 1999, 399 (6738) :A32-A39
[9]   AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY [J].
FEARNLEY, JM ;
LEES, AJ .
BRAIN, 1991, 114 :2283-2301
[10]   1,25-dihydroxyvitamin D-3 regulates gamma-glutamyl transpeptidase activity in rat brain [J].
Garcion, E ;
Thanh, XD ;
Bled, F ;
Teissier, E ;
Dehouck, MP ;
Rigault, F ;
Brachet, P ;
Girault, A ;
Torpier, G ;
Darcy, F .
NEUROSCIENCE LETTERS, 1996, 216 (03) :183-186